Incidence of invasive meningococcal disease is low in Germany at 0.5 cases/100,000 inhabitants. Serogroup B (MenB) is most common, causing 70% of cases, with highest incidence in infants (5.9/100,000). In 2013, a MenB vaccine was licensed in Europe. To assess pediatricians' attitudes towards MenB vaccination and its potential use in Germany we conducted a nationwide cross-sectional survey among 5677 pediatricians. Of 3107 participants (response: 55%), 79.1% would recommend a MenB vaccination to parents, with 66.7% favoring a schedule at 6, 8 and 12 months over 2, 3, 4 and 12 months (13.4%). Administration separately from other vaccines was preferred (63.2%); 38.5% feared that a recommendation would lead to refusal of other recommended vaccinations. In conclusion, pediatricians showed distinct preferences regarding possible integration of MenB vaccination into the existent immunization schedule. As physicians play a crucial role in the implementation, findings will be useful in decision-making regarding potential introduction.
Background
In Germany, the incidence of invasive meningococcal disease (IMD) has shown a decreasing trend since 2003, with a mean annual incidence of 0.5 cases/100,000 inhabitants in 2009-2011. This is lower than the mean incidence in Europe of 0.8 in 2011, and markedly lower than in Ireland (2.0), the UK (1.7) or Spain (1.0) [1] . Approximately 70% of IMD was caused by meningococcal serogroup B (MenB), with a case-fatality of 8.2% [2] . MenB IMD incidence was highest in infants (mean: 5.9/100,000; 16% of all cases), followed by 1, 2 and 15-19 year olds (3.3, 1.7 and 1.1/100,000, respectively). Of cases in infants, 48% occurred in the first 6 months of life. Longterm sequelae such as hearing loss, neurological defects or amputations have been reported in up to ∼20% of cases [3, 4] .
In January 2013, the European Medicines Agency licensed 4CMenB (Bexsero ® ), a novel multi-component MenB vaccine based on subcapsular proteins [5] . Strain coverage for Germany was estimated at 82% [6] . In pre-licensure studies, the vaccine induced satisfactory immunogenicity; but definitive data on effect on meningococcal carriage, vaccine effectiveness and rare adverse events are still pending [7] . The number of required doses varies from 2 to 3 primary immunizations with/without 1 booster, depending on age at first dose [8] . Reactogenity of Bexsero ® is increased particularly in infants when administered concomitantly with routine vaccines (Infanrix hexa ® and Prevenar ® ) compared to routine vaccines only or Bexsero ® only [9] .
Bexsero ® was marketed in Germany in December 2013. To be included in the German national immunization schedule and reimbursed by statutory health insurance, a new vaccine must be recommended by the German Standing Committee on Vaccination (STIKO). STIKO recommendations are officially endorsed by 15 of the 16 federal states. While not legally binding, these recommendations are considered the medical standard in liability cases [10] . The currently recommended infant immunization schedule is shown in Fig. 1 . Childhood immunizations are almost exclusively administered by privately practicing pediatricians on a fee-for-service basis [11] . In developing evidence-based recommendations, STIKO follows a standard operating procedure to evaluate all available evidence on vaccine efficacy/effectiveness and safety, but also on other aspects, such as implementability of the potential recommendation, including possible obstacles and likely acceptance of the vaccine [12] . Physicians play a crucial role for acceptance: in a representative survey among parents in Germany, 93% indicated that the physician was the main source of information regarding vaccination [13] . Another German study found that physicians' attitudes toward vaccination are predictive of vaccination coverage [14] . Similarly, a survey in Australia described that parents' potential willingness to have their child receive Bexsero ® was most strongly influenced by a recommendation of the family doctor [15] .
The aim of our study was to assess attitudes among pediatricians towards MenB vaccination and its potential use in Germany, with an emphasis on the perceived need for such a vaccine, the feasibility of integrating it into the existing immunization schedule and possible implications for other routine childhood vaccinations.
Material and methods
In November 2013, we conducted a nationwide cross-sectional survey among the 5677 privately practicing pediatricians with membership in the German Professional Association for Pediatricians (BVKJ), representing 96% of all privately practicing pediatricians in Germany [16] .
A written questionnaire was developed that included items on participants' demographics (age, sex, practice location, years spent in pediatric practice and board certification status), as well as on their views regarding a possible MenB vaccine recommendation and administration ( Table 1 ). The questionnaire was pre-tested by 15 pediatricians and subsequently posted to all eligible members, accompanied by a cover letter and one-page background information on Bexsero ® and MenB IMD epidemiology in Germany.
Returned questionnaires were double-entered electronically using EpiData version 3.1 (EpiData Association, Denmark). A descriptive analysis was performed, including calculation of proportions and 95% confidence intervals (CI). Demographic data on participants were compared to available BVKJ-member information. Due to Germany's geographical size and historical differences, we performed regional analyses. We explored associations using the Chi-squared Test and univariate logistic regression, followed by stratification for duration in private practice, sex and region to estimate odds ratios (ORs) with 95% CIs. Statistical analysis was performed using Stata ® version 13 (StataCorp, Texas, USA).
Results and discussion
Of the 5677 questionnaires sent out, 3107 (55%) were returned. Respondents' mean age was 53 years (all BVKJ-members: 54 years), 52% were male (all members: 50%), and response ranged from 53-58% per region. Mean duration in pediatric practice was 16 years, and 99% (n = 3070) were board-certified pediatricians.
Participants' responses are summarized in Table 1 . The majority (79.1%) stated they would recommend MenB vaccination. The most common reasons given for not recommending the vaccine were a concern that the schedule would become overcrowded and insufficient data on potential rare adverse events. Children ≤24 months were most frequently specified as target groups for MenB vaccination, in keeping with the highest incidence at these ages. Two thirds of participants believed that parents would be acceptant of an official STIKO recommendation.
Of two possible licensed vaccine schedules integrating MenB vaccination into the current German routine immunization schedule, vaccination at month 6, 8 and 12 of age (Option 2, Fig. 1 ) was preferred by 66.7% of physicians (95%CI 65.0-68.3; n = 2070), whereas vaccination at month 2, 3, 4 and 12 (Option 1, Fig. 1 ) was favored by only 13.4% (95%CI 12.2-14.6; n = 416). Neither schedule was chosen by 14% (95%CI 13.0-15.5; n = 441). Of these, 59.6% (95%CI 54.9-64.3%; n = 263) indicated they would vaccinate in the first 6 months of life but at different time points than in Option 1. In keeping with the strong preference for Option 2, only 31.3% of all respondents thought MenB vaccination should be administered concomitantly with other standard vaccinations. Similarly, >70% of all participants objected in principle to the simultaneous administration of 3 vaccines; 19.7% among those favoring Option 1 and 81.8% among those favoring Option 2 (p < 0.005). The most common reason given for objection was lack of parental acceptance ( Table 1) .
Approximately 40% of all respondents thought that recommendation of MenB vaccine would lead to refusal of other recommended vaccinations (Table 1 ). It seems surprising that physicians thought parents would most likely forego pneumococcal vaccination if MenB vaccination were introduced, since this is a disease at least as severe as MenB IMD with a higher prevaccination incidence [17] , but maybe less in the focus of privately practicing than of hospital-based pediatricians [18] . However, the other three vaccines named in this context either protect against diseases that are perceived as less severe (rotavirus, varicella) or with a lower risk of infection than MenB IMD (MenC).
Age, sex, region and years spent in pediatric practice had a significant effect on some of the responses ( Table 2 ). As age of pediatrician and years in practice were highly correlated (Pearson's correlation coefficient = 0.83, p < 0.005), we present results only for the latter. Female physicians and physicians in practice ≥10 years were less likely to fear refusal of other recommended vaccines if MenB vaccination were introduced, but were more likely to object to simultaneous administration of three vaccines or concomitant MenB vaccination and other vaccines. Correspondingly, female physicians were less likely to prefer Option 1 than their male colleagues, especially females in practice >10 years (see Appendix). Compared to pediatricians from Northern states, pediatricians from Western and Eastern states were more likely and pediatricians from Southern states less likely to believe that parents would be acceptant of MenB vaccination. Southern pediatricians were also more likely to fear refusal of other vaccines if MenB vaccination were recommended, particularly if in practice <10 years, while those in Eastern states were less likely to fear this, particularly those in practice ≥20 years (Appendix). This corresponds with a lower uptake of standard vaccines in Southern states than in other parts of Germany [19] , possibly explained by a higher percentage of anthroposophists/vaccine-sceptics in their population [20, 21] and a less positive physicians' attitude towards vaccination [14] . In contrast, uptake of standard vaccines is highest in Eastern Germany [19] , where pediatricians, particularly female pediatricians (Appendix), were most likely to recommend MenB vaccination. Nonetheless, Eastern pediatricians were also more likely to object to simultaneous administration of 3 vaccines and prefer Option 2. Regional differences among German physicians were also seen in a previous study regarding attitude towards pertussis and measles vaccination [14] .
As physicians play a crucial role in the implementation and acceptance of new vaccines, assessment of their views is essential. So far, results from only one other study, conducted in 2012 in France, are available on the attitude of pediatricians and general practitioners towards MenB vaccination [22] . In this study, 96% of responding physicians thought MenB vaccination important, but 81% were against administering three vaccines simultaneously and 54% favored administering MenB vaccine separately from other vaccinations-results comparable to ours. Thus, the addition of Bexsero ® to an already busy vaccination schedule appears challenging, at least in the first 6 months of life, primarily due to widespread reluctance to administer three injections simultaneously and thus to administer Bexsero ® concomitantly with currently recommended standard vaccines. Moreover, 90%
of pediatricians who objected to three simultaneous injections believed that parents would also object to this. A recent review of mostly North American studies on provider and parental attitudes towards multiple injections [23] showed that provider acceptance of >2 injections increased when official recommendations required this. Providers also tended to overestimate parental concern, and reassurance by physicians as well as an understanding of the severity of the target disease increased parental acceptance of multiple injections. While parental objection to >2 injections per visit was also reported in a recent study from The Netherlands [24] , with a majority of parents preferring an extra visit, half said they would probably accept three vaccinations if actually offered. Similarly, the Australian survey showed that a third injection per visit made only 15% of parents less likely to want MenB vaccine for their child [15] . However, none of the studies, including the latter, explicitly investigated whether parental acceptance for concomitant vaccination would be affected by the information that concomitant vaccination was shown to be more reactogenic than alternating injections. Taken together, our results suggest that if STIKO should recommend MenB vaccination for infants from 2 months of age on completion of the evidence assessment, it would be essential to provide pediatricians with a convincing rationale and strong arguments for concomitant vaccination, to ensure successful implementation and to avoid the dropping of other equally or even more important vaccinations by physicians or parents. This should include evidence suggesting that parents can be convinced to accept three simultaneous injections by their physicians. Since MenB incidence is highest in the first year of life, with about half of cases occurring <6 months of age, early vaccination would prevent the most cases. Nonetheless, in Germany 59% of cases in the first 3 years of life occur in children aged 9 months and older, the age-span in which protection would be expected using the later 3-dose schedule. An additional 21% of cases in children <3 years of age occur in children from 5 to 8 months of age (unpublished data, Robert Koch Institute), potentially preventable through earlier vaccination. Thus, in view of the currently low incidence in Germany and overwhelming preference for administration of MenB vaccine separately from routine vaccines, implementation at a later age, requiring fewer doses, might lead to higher uptake and thereby have similar or higher impact. A modeling exercise comparing the impact of different vaccination strategies at the population level is currently being carried out for Germany and will inform STIKO decision-making in addition to other data such as the results derived from the present survey. Table A1 . 
